Takeda-Innovent closes USD11.4B immuno-oncology partnership

JAPAN/USA—Takeda and Innovent have officially closed their global partnership focused on developing next-generation immuno-oncology and antibody-drug conjugate therapies.

The collaboration moves forward after both companies fulfilled all necessary closing conditions.

The two pharmaceutical giants originally signed the agreement in October 2025, establishing a framework centered on bispecific antibodies and ADCs.

Through this partnership, they aim to accelerate the worldwide development and commercialization of Innovent’s advanced cancer treatment portfolio.

The deal encompasses three key therapeutic candidates: IBI363, IBI343, and an early-stage option for IBI3001.

IBI3001 represents an epidermal growth factor receptor and B7 homolog 3 antibody-drug conjugate currently undergoing Phase I clinical trials.

Under the partnership structure, both companies will jointly develop IBI363 globally while co-commercializing it within the United States.

Takeda will lead the joint governance framework and oversee the unified development strategy for this therapy.

Meanwhile, Innovent has granted Takeda exclusive commercialization rights for IBI363 in all territories outside the US and Greater China.

Takeda holds global manufacturing rights to produce and supply IBI363 for markets beyond Greater China.

The companies will share commercial supply responsibilities within the US market.

Additionally, Takeda secured an exclusive option to license global rights for IBI3001 outside Greater China, pending the completion of ongoing clinical development.

The financial terms reflect the partnership’s substantial scope and potential.

Takeda will pay Innovent an upfront sum of USD1.2 billion, which includes a $100 million equity investment through newly issued shares priced at HK$112.56 (USD14.46) per share.

Beyond the initial payment, Innovent stands to receive development and sales milestone payments totaling up to USD10.2 billion across all three molecules.

This brings the potential overall transaction value to USD11.4 billion, representing one of the pharmaceutical industry’s most significant recent collaborations.

The revenue-sharing arrangement varies by geography and product. Innovent will receive royalty payments for each molecule outside Greater China, with one notable exception.

For IBI363 sales in the US, the companies will share profits and losses, with Innovent receiving 40 percent and Takeda taking 60 percent.

Dr. Hui Zhou, Innovent’s oncology pipeline chief research and development officer, emphasized the partnership’s strategic importance.

He highlighted how IBI363 and IBI343 represent next-generation therapies designed to address significant unmet needs in global cancer treatment.

Dr. Zhou expressed confidence that combining Innovent’s deep asset knowledge with Takeda’s extensive development and commercialization capabilities will maximize the clinical potential of these therapies across multiple cancer indications.